New Insight Into Metformin Action: Diabetes, Prostate Cancer, Ion Channels

Abstract

Diabetes Mellitus is a lifelong chronic metabolic disease, requiring continuous follow-up and therapy, it reduces the quality of life of patients with acute and chronic complications, mortality, and its economic burden is high. Cancer is the second cause of death, according to World Health Organization data.  Prostate cancer is one of the most common cancers in the developed world and the second leading cause of male cancer related death. As with other cancer types, metastasis is an essential problem that we are facing and it is not clear whether a tumor will metastasize or not in localized state.  It has been reported that there are high levels of voltage-gated sodium channels in metastatic prostate cancer cases. Cancer, ever growing with diabetes, is a major health problem. Studies have shown that diabetic patients have higher cancer rates than those of non-diabetics. Metformin is the drug of choice for the treatment of diabetes. Recently, there are studies in the literature regarding metformin reducing the risk of cancer besides its effect on diabetes This review will explain the possible role of the metformın on the three dimensional relationship of prostate cancer, dıabetes andion channels, and  provide a significant contribution to clinical trials.

Keywords:  Cancer, experimental diabetes, metformin, voltage gated sodium channel, MAT-Lylu cells

Keywords

• Cancer, experimental diabetes, metformin, voltagegated sodium channel, MAT-Lylu cells

References

1. Öntürk H, Özbek H. Deneysel diyabet oluşturulması ve kan şeker seviyesinin ölçülmesi. Genel Tıp Dergisi 2007; 17: 231-6.
2. Aybek H, Aybek Z, Rota S, Sen N, Akbulut M. The effects of diabetes mellitus, age, and vitamin E on testicular oxidative stress. Fertil Steril 2008; 90: 755-60.
3. Fajans SS Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34: 1878– 1884.
4. Flannick J, Johansson S, Njİlstad PR. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Rev Endocrinol 2016; [Epub ahead of print].
5. Sicree R, Shaw J and Zimmet P. The Global Burden. Diabetes and Impaired Glucose Tolerance. Prevalence and Projections. In: Diabetes Atlas, 3rd edn. Editor: Gan D. Brussels: International Diabetes Federation. Brussels. 2006, pp. 16-103.
6. World Health Organization (WHO). 2014. Fact Sheet No. 297.
7. Maine EA, Westcott JW, Prechtl AM, Dang TT, Whitehurst AW, Pearson GW. The cancer/testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget 2016; [Epub ahead of print].
8. American C. 2014. Prostate Cancer: Detailed Guide. Available from http://www.cancer.org/cancer/prostatecancer/ detailedguide/ prostate-cancer-key-statistics. [Last accessed: 27.04.2016].

9. Siegel R, Ma J, Zou Z, Jemal A. A cancer statistics. CA Cancer J. Clin 2014; 64 : 9–29.
10. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostatic cancer: a meta- analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 618-24.
11. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostatic cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 2013; 16: 151-8.
12. Yang RH, Wang WT, Chen JY, Xie RG, Hu SJ. Gabapentin selectively reduces persistent sodium current in injured type-A dorsal root ganglion neurons. Pain 2009; 143: 48-55.
13. Goldin AL, Barchi RL, Caldwell JH, Hoffman F, Howe JR, Hunter JC, Kallen RG., Mandelisler MH, Netter YB, Noda M, Tamkun MM, Waxman SG, Wood JN, Catterall WA. Nomenclature of voltage gated sodium channels. Neuron 2000; 28: 365-8.
14. Nakajıma T, Kubota N, Tsutsumı T, Ogurı A, Imuta HT, Oonuma H, Soma M, Meguro K, Takano H, Nagase T, Nagata T. Eicosapentaenoic acid inhibits voltage-gated sodium channels and invasiveness in prostatic cancer cells. Br J Pharmacol 2009; 156: 420-31.
15. Gao R, Shen Y, Cai J, Leı M, Wang Z. Expression of voltage gated sodium channel subunit in human ovarian cancer. Oncol Rep 2010; 23: 1293-9.
16. Fraser SP, Ozerlat-Gunduz I, Brackenbury WJ, Fitzgerald EM, Thomas M, Campbell TM, Coombes RC, Djamgoz MBA. Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation. Phil Trans R Soc B 2014; 369: 20130105.
17. Onganer PU, Djamgoz MBA. Epidermal growth factor potentiates in vitro metastatic behaviour of human prostatic cancer PC-3M cells: Involvement of voltage-gated sodium channel. Mol Cancer 2007; 6: 76-88.
18. Mycielska ME, Palmer CP, Brackenbury WJ, Djamgoz MB. Expression of Na+-dependent citrate transport in a strongly metastatic human prostate cancer PC-3M cell line: regulation by voltage-gated Na+ channel activity. J Physiol 2005;563:393- 408.
19. Ding Y, Brackenbury WJ, Onganer PU, Montano X, Porter LM, Bates LF, Djamgoz MBA. Epidermal growth factor upregulates motility of Mat-lylu rat prostatic cancer cells partially via voltage-gated NaR channel activity. J Cell Physiol 2008; 215: 77-81.
20. Hursting SD, Nunez NP, Varticovski L,Vinson C. The obesity– cancer link: lessons learned from a fatless mouse. Cancer Res 2007; 67: 2391-3.
21. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM,